Cancer clinical trials in the region Occitanie

174 currently recruiting clinical trials
Region Occitanie

Phase 2 Breast cancer
#NCT05563220
HER2 Negative HR Positive Locally Advanced Metastatic Hormone therapy 1 2
Chemotherapy
7 main criterias to confirm
Centre Hospitalier Universitaire de Toulouse (Toulouse), Centre de Cancérologie du Grand Montpellier (Montpellier)
Stemline Therapeutics, Inc.
Phase 2 Liver and bile duct cancer
#NCT05528952
Hepatocellular carcinoma Locally Advanced Metastatic Systemic Treatment-Naive None Unhealthy A
Immunotherapy
8 main criterias to confirm
Centre Hospitalier Universitaire de Montpellier - Site Arnaud de Villeneuve (Montpellier)
CHU de Besançon
Phase 2 Lung cancer
#NCT05384626
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic ALK Immunotherapy Chemotherapy Targeted therapy 1 2 3 or more
Systemic Treatment-Naive
7 main criterias to confirm
IUCT Oncopôle (Toulouse)
Nuvalent Inc.
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer
#NCT05384626
Locally Advanced Metastatic Metastatic Castration-resistant ALK 1 2 3 or more
AKT ATM BRAF BRCA 1/2 CDK12 CHEK 1/2 ESR FGFR HER2 HOXB13 KRAS G12C KRAS non G12C MET MSI/dMMR NRAS NTRK-1/2/3 PALB2 PIK3CA PTEN RET Systemic Treatment-Naive
6 main criterias to confirm
IUCT Oncopôle (Toulouse)
Nuvalent Inc.
Phase 2 Liver and bile duct cancer
#NCT05325866
Intrahepatic cholangiocarcinoma Locally Advanced Metastatic FGFR 1 2 3 or more
Systemic Treatment-Naive
6 main criterias to confirm
IUCT Oncopôle (Toulouse), Institut du cancer de Montpellier (Montpellier)
Amgen
Phase 2 Lung cancer
#NCT05325866
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic FGFR Immunotherapy Chemotherapy Targeted therapy 1 2 3 or more
Systemic Treatment-Naive
7 main criterias to confirm
IUCT Oncopôle (Toulouse), Institut du cancer de Montpellier (Montpellier)
Amgen
Phase 2 Breast cancer
#NCT05325866
HER2 Negative HR Negative Locally Advanced Metastatic FGFR 2 3 or more
Systemic Treatment-Naive
7 main criterias to confirm
IUCT Oncopôle (Toulouse), Institut du cancer de Montpellier (Montpellier)
Amgen
Phase 2 Breast cancer
#NCT05297617
HER2 Negative HR Positive Localized Surgery Hormone therapy None
Chemotherapy
7 main criterias to confirm
Clinique des Cèdres - Ramsay Santé (Cornebarrieu)
UNICANCER
Phase 2 Breast cancer
#NCT05296746
HER2 Negative HR Positive Locally Advanced Systemic Treatment-Naive Systemic Treatment-Naive None
7 main criterias to confirm
IUCT Oncopôle (Toulouse), Institut Sainte Catherine (Avignon)
Novartis
Phase 2 Lung cancer
#NCT05142696
SCLC (Small Cell Lung Cancer) Locally Advanced Metastatic Systemic Treatment-Naive None
Immunotherapy
6 main criterias to confirm
Centre Hospitalier Universitaire de Montpellier - Site Arnaud de Villeneuve (Montpellier)
Novartis